ANTIGEN-ANTIBODY COMPLEXES IN BREAST CANCER

乳腺癌中的抗原抗体复合物

基本信息

  • 批准号:
    3166984
  • 负责人:
  • 金额:
    $ 9.54万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1979
  • 资助国家:
    美国
  • 起止时间:
    1979-05-01 至 1986-07-31
  • 项目状态:
    已结题

项目摘要

The objective of this study is to assay soluble antigen-antibody complexes in serum of patients with breast cancer using C1q binding radioimmunoassay, Raji cell radioimmunoassay, and (rabbit) rheumatoid factor assay. The serum specimens will be obtained from breast cancer patients, fibrocystic breast disease patients and breast cancer families as well as from appropriate healthy control individuals. The breast cancer patients will be longitudinally followed for evaluation of the response to treatment in order to determine the prognostic and monitoring values of the assay. The high risk groups (fibrocystic breast disease and breast cancer families) are also to be followed in order to evaluate the diagnostic potential of the immune complex assay. The antigen-antibody complexes are also to be isolated from the serum and body fluids (pleural effusion) of breast cancer patients by molecular exclusion chromatography, protein A affinity chromatography and immunoadsorption using affinity media to the Fc domain of IgG. Further, the isolated immune complexes will be dissociated under the least denaturing conditions. The dissociated antigens are to be characterized biochemically and immunologically. Xenobiotic antisera will be raised with the dissociated antigen(s) and with isolated complexes as well as with the Raji cells containing surface-bound immune complexes injected into rabbits made tolerant to human IgG, and studied by their ability to recombine the dissociated antigen and to bind malignant breast tissues. In vitro antibody-dependent cell-mediated cytotoxicity, lymphocyte mitogenesis, PHA-induced lymphocyte blastogenesis and LAI assays are also to be performed to study the possible biological function of antibody-antigen complexes. Further, a radioimmunoassay will be developed which may be of use in early detection and monitoring of efficacy of therapy for breast cancer.
本研究的目的是测定可溶性抗原抗体复合物, 乳腺癌患者血清C1 q结合放射免疫分析,Raji 细胞放射免疫测定和(兔)类风湿因子测定。 血清 样本将从乳腺癌患者、纤维囊性乳腺癌患者和乳腺癌患者中获得。 疾病患者和乳腺癌家庭以及适当的健康 控制个人。 将对乳腺癌患者进行纵向随访 用于评价治疗反应,以确定预后 和监测测定的值。 高危人群(纤维囊性乳腺癌) 疾病和乳腺癌家族),以评估 免疫复合物测定的诊断潜力。 抗原-抗体 复合物也可以从血清和体液(胸膜炎)中分离 渗出液)的乳腺癌患者的细胞, 蛋白A亲和层析和使用亲和介质的免疫吸附, IgG的Fc结构域。 此外,分离的免疫复合物将是 在最小变性条件下解离。 解离的抗原是 进行生化和免疫学鉴定。 异源抗血清将 用解离的抗原和分离的复合物以及 将含有表面结合免疫复合物的Raji细胞注射到 兔耐受人IgG,并通过其重组能力进行研究, 解离的抗原并结合恶性乳腺组织。 体外 抗体依赖性细胞介导的细胞毒性,淋巴细胞有丝分裂, 还将进行PHA诱导的淋巴细胞胚细胞生成和LAI测定, 研究抗体-抗原复合物可能的生物学功能。 此外,本发明还 将开发一种放射免疫测定法,可用于早期检测, 监测乳腺癌治疗的疗效。

项目成果

期刊论文数量(11)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(1)
Experimental tumoricidal effects of monoclonal antibody against solid breast tumors.
单克隆抗体对实体乳腺肿瘤的实验性杀瘤作用。
Relationship between antigen density and immunotherapeutic response elicited by monoclonal antibodies against solid tumors.
抗原密度与针对实体瘤的单克隆抗体引起的免疫治疗反应之间的关系。
Monoclonal antibodies (F36/22 and M7/105) to human breast carcinoma.
针对人乳腺癌的单克隆抗体(F36/22 和 M7/105)。
  • DOI:
  • 发表时间:
    1983
  • 期刊:
  • 影响因子:
    11.2
  • 作者:
    Papsidero,LD;Croghan,GA;O'Connell,MJ;Valenzuela,LA;Nemoto,T;Chu,TM
  • 通讯作者:
    Chu,TM
Hybridoma antibody to breast cancer immune complexes.
乳腺癌免疫复合物的杂交瘤抗体。
  • DOI:
    10.1089/hyb.1.1982.1.275
  • 发表时间:
    1982
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Papsidero,LD;Nemoto,T;Valenzuela,L;Chu,TM
  • 通讯作者:
    Chu,TM
Potential applications of monoclonal antibodies in cancer diagnosis and therapy.
单克隆抗体在癌症诊断和治疗中的潜在应用。
  • DOI:
    10.3109/07357908509039818
  • 发表时间:
    1985
  • 期刊:
  • 影响因子:
    2.4
  • 作者:
    Chu,TM
  • 通讯作者:
    Chu,TM
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Tsann Ming Chu其他文献

Tsann Ming Chu的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Tsann Ming Chu', 18)}}的其他基金

TARGETING AND THERAPY OF TUMORS WITH MONOCLONAL ANTIBODY
用单克隆抗体靶向和治疗肿瘤
  • 批准号:
    3175435
  • 财政年份:
    1984
  • 资助金额:
    $ 9.54万
  • 项目类别:
TARGETING AND THERAPY OF TUMORS WITH MONOCLONAL ANTIBODY
用单克隆抗体靶向和治疗肿瘤
  • 批准号:
    3175437
  • 财政年份:
    1984
  • 资助金额:
    $ 9.54万
  • 项目类别:
TARGETING AND THERAPY OF TUMORS WITH MONOCLONAL ANTIBODY
用单克隆抗体靶向和治疗肿瘤
  • 批准号:
    3175434
  • 财政年份:
    1984
  • 资助金额:
    $ 9.54万
  • 项目类别:
TARGETING AND THERAPY OF TUMORS WITH MONOCLONAL ANTIBODY
用单克隆抗体靶向和治疗肿瘤
  • 批准号:
    3175432
  • 财政年份:
    1984
  • 资助金额:
    $ 9.54万
  • 项目类别:
TARGETING AND THERAPY OF TUMORS WITH MONOCLONAL ANTIBODY
用单克隆抗体靶向和治疗肿瘤
  • 批准号:
    3175436
  • 财政年份:
    1984
  • 资助金额:
    $ 9.54万
  • 项目类别:
BREAST CARCINOMA ANTIGENS F36/22 AND M7/105
乳腺癌抗原 F36/22 和 M7/105
  • 批准号:
    3172050
  • 财政年份:
    1983
  • 资助金额:
    $ 9.54万
  • 项目类别:
BIOLOGICAL MARKERS IN TREATMENT OF PROSTATE CANCER
治疗前列腺癌的生物标志物
  • 批准号:
    3556295
  • 财政年份:
    1979
  • 资助金额:
    $ 9.54万
  • 项目类别:
ANTIGEN MARKERS IN DIAGNOSIS OF PROSTATE CANCER
诊断前列腺癌的抗原标记
  • 批准号:
    3164177
  • 财政年份:
    1976
  • 资助金额:
    $ 9.54万
  • 项目类别:

相似海外基金

Development of a screening diagnostic for the detection of viruses and bacteria from body fluids that utilizes the unparalleled structural characterization of mass spectrometry
利用无与伦比的质谱结构表征,开发用于检测体液中病毒和细菌的筛查诊断方法
  • 批准号:
    10728116
  • 财政年份:
    2023
  • 资助金额:
    $ 9.54万
  • 项目类别:
Metagenomic analysis of tissues and body fluids in neonatal hepatitis and encephalitis
新生儿肝炎和脑炎组织和体液的宏基因组分析
  • 批准号:
    22K19494
  • 财政年份:
    2022
  • 资助金额:
    $ 9.54万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Liquid biopsy for Rhabdoid tumor by Exoxomal-microRNAs in blood and other body fluids
利用血液和其他体液中的 Exoxomal-microRNA 对横纹肌样瘤进行液体活检
  • 批准号:
    21K07778
  • 财政年份:
    2021
  • 资助金额:
    $ 9.54万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
16S rRNA gene sequencing-based exploring bacterial DNA markers for the identification of forensically relevant body fluids from degraded samples
基于 16S rRNA 基因测序的探索细菌 DNA 标记,用于从降解样品中鉴定法医相关体液
  • 批准号:
    21K21033
  • 财政年份:
    2021
  • 资助金额:
    $ 9.54万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Dirty Linen: the forensic soft matter science of body fluids on fabric
脏亚麻布:织物上体液的法医软物质科学
  • 批准号:
    2515837
  • 财政年份:
    2020
  • 资助金额:
    $ 9.54万
  • 项目类别:
    Studentship
Development of radiotherapy combined with a new diagnostic marker for body fluids that enables ultra-minimally invasiveness
开发出与新型体液诊断标志物相结合的放射疗法,可实现超微创
  • 批准号:
    19K17140
  • 财政年份:
    2019
  • 资助金额:
    $ 9.54万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Identification of circulating microRNA in body fluids associated with growth and rupture of cerebral aneurysm
体液中与脑动脉瘤生长和破裂相关的循环 microRNA 的鉴定
  • 批准号:
    19K18439
  • 财政年份:
    2019
  • 资助金额:
    $ 9.54万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Development of a comprehensive procedure for determination of multiple body fluids by multiplex reverse transcription-PCR
开发通过多重逆转录 PCR 测定多种体液的综合程序
  • 批准号:
    18K10138
  • 财政年份:
    2018
  • 资助金额:
    $ 9.54万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Analysis of chemical exposure effects in human mothers and children through metabolomic analysis of body fluids and feces
通过体液和粪便的代谢组学分析分析人类母亲和儿童的化学暴露影响
  • 批准号:
    18K18199
  • 财政年份:
    2018
  • 资助金额:
    $ 9.54万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Accurate measurement of natural toxins in body fluids using deuterated standards and search of specific markers for the rapid diagnosis
使用氘化标准品准确测量体液中的天然毒素并搜索特定标记物以进行快速诊断
  • 批准号:
    18H03064
  • 财政年份:
    2018
  • 资助金额:
    $ 9.54万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了